Publication Trends of Leber Congenital Amaurosis Researches: a Bibliometric Study During 2002-2022

Overview

Journal Int J Ophthalmol

Specialty Ophthalmology

Date 2024 Aug 19

PMID 39156783

Authors

Xiao-Xu Huang

Yi-Min Wang

Min-Yue Xie

Yi-Qing Sun

Xiao-Huan Zhao

Yu-Hong Chen

Jie-Qiong Chen

Si-Yang Han

Min-Wen Zhou

Xiao-Dong Sun

Affiliations

Soon will be listed here.

Abstract

Aim: To analyze the changes in scientific output relating to Leber congenital amaurosis (LCA) and forecast the study trends in this field.

Methods: All of the publications in the field of LCA from 2002 to 2022 were collected from Web of Science (WOS) database. We analyzed the quantity (number of publications), quality (citation and H-index) and development trends (relative research interest, RRI) of published LCA research over the last two decades. Moreover, VOSviewer software was applied to define the co-occurrence network of keywords in this field.

Results: A total of 2158 publications were ultimately examined. We found that the focus on LCA kept rising and peaked in 2015 and 2018, which is consistent with the development trend of gene therapy. The USA has contributed most to this field with 1162 publications, 56 674 citations and the highest H-index value (116). The keywords analysis was divided into five clusters to show the hotspots in the field of LCA, namely mechanism-related, genotype-related, local phenotype-related, system phenotype-related, and therapy-related. We also identified gene therapy and anti-retinal degeneration therapy as a major focus in recent years.

Conclusion: Our study illustrates historical research process and future development trends in LCA field. This may help to guide the orientation for further clinical diagnosis, treatment and scientific research.

References

Russell S, Drack A, Cideciyan A, Jacobson S, Leroy B, Van Cauwenbergh C . Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial. Nat Med. 2022; 28(5):1014-1021. PMC: 9117145. DOI: 10.1038/s41591-022-01755-w. View

Chiu W, Lin T, Chang Y, Isahwan-Ahmad Mulyadi Lai H, Lin S, Ma C . An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials. Int J Mol Sci. 2021; 22(9). PMC: 8123696. DOI: 10.3390/ijms22094534. View

Glanville J, Kendrick T, McNally R, Campbell J, Hobbs F . Research output on primary care in Australia, Canada, Germany, the Netherlands, the United Kingdom, and the United States: bibliometric analysis. BMJ. 2011; 342:d1028. PMC: 3050436. DOI: 10.1136/bmj.d1028. View

Garanto A, Chung D, Duijkers L, Corral-Serrano J, Messchaert M, Xiao R . In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery. Hum Mol Genet. 2016; 25(12):2552-2563. PMC: 6086559. DOI: 10.1093/hmg/ddw118. View

Kumaragurupari R, Mishra C . A bibliometric analysis of research on genetic retinal diseases done in India. Indian J Ophthalmol. 2022; 70(7):2546-2550. PMC: 9426062. DOI: 10.4103/ijo.IJO_3154_21. View

Xu K, Xie Y, Sun T, Zhang X, Chen C, Li Y . Genetic and clinical findings in a Chinese cohort with Leber congenital amaurosis and early onset severe retinal dystrophy. Br J Ophthalmol. 2019; 104(7):932-937. DOI: 10.1136/bjophthalmol-2019-314281. View

Hamel C . Retinitis pigmentosa. Orphanet J Rare Dis. 2006; 1:40. PMC: 1621055. DOI: 10.1186/1750-1172-1-40. View

Stepanova A, Ogorodova N, Kadyshev V, Shchagina O, Kutsev S, Polyakov A . A Molecular Genetic Analysis of RPE65-Associated Forms of Inherited Retinal Degenerations in the Russian Federation. Genes (Basel). 2023; 14(11). PMC: 10671290. DOI: 10.3390/genes14112056. View

Chen T, Huang D, Lin C, Yang C, Yang C, Wang V . Genetic characteristics and epidemiology of inherited retinal degeneration in Taiwan. NPJ Genom Med. 2021; 6(1):16. PMC: 7896090. DOI: 10.1038/s41525-021-00180-1. View

10.

Kokol P, Blazun Vosner H, Zavrsnik J . Application of bibliometrics in medicine: a historical bibliometrics analysis. Health Info Libr J. 2020; 38(2):125-138. DOI: 10.1111/hir.12295. View

11.

Jacobson S, Cideciyan A, Roman A, Sumaroka A, Schwartz S, Heon E . Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med. 2015; 372(20):1920-6. PMC: 4450362. DOI: 10.1056/NEJMoa1412965. View

12.

Georgiou M, Fujinami K, Michaelides M . Inherited retinal diseases: Therapeutics, clinical trials and end points-A review. Clin Exp Ophthalmol. 2021; 49(3):270-288. DOI: 10.1111/ceo.13917. View

13.

Huang C, Yang C, Yang C, Hou Y, Chen T . Leber's Congenital Amaurosis: Current Concepts of Genotype-Phenotype Correlations. Genes (Basel). 2021; 12(8). PMC: 8392113. DOI: 10.3390/genes12081261. View

14.

Schneider N, Sundaresan Y, Gopalakrishnan P, Beryozkin A, Hanany M, Levanon E . Inherited retinal diseases: Linking genes, disease-causing variants, and relevant therapeutic modalities. Prog Retin Eye Res. 2021; 89:101029. DOI: 10.1016/j.preteyeres.2021.101029. View

15.

Maguire A, High K, Auricchio A, Wright J, Pierce E, Testa F . Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009; 374(9701):1597-605. PMC: 4492302. DOI: 10.1016/S0140-6736(09)61836-5. View

16.

MacDonald I, Sieving P . American Journal of Ophthalmology Contributions to Ophthalmic Genetics. Am J Ophthalmol. 2018; 190:xvi-xxi. DOI: 10.1016/j.ajo.2018.03.004. View

17.

Sweeney M, McGee T, Berson E, Dryja T . Low prevalence of lecithin retinol acyltransferase mutations in patients with Leber congenital amaurosis and autosomal recessive retinitis pigmentosa. Mol Vis. 2007; 13:588-93. PMC: 2669503. View

18.

Bainbridge J, Mehat M, Sundaram V, Robbie S, Barker S, Ripamonti C . Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med. 2015; 372(20):1887-97. PMC: 4497809. DOI: 10.1056/NEJMoa1414221. View

19.

Weleber R, Pennesi M, Wilson D, Kaushal S, Erker L, Jensen L . Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy. Ophthalmology. 2016; 123(7):1606-20. DOI: 10.1016/j.ophtha.2016.03.003. View

20.

Maguire A, Bennett J, Aleman E, Leroy B, Aleman T . Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy. Mol Ther. 2020; 29(2):442-463. PMC: 7854308. DOI: 10.1016/j.ymthe.2020.11.029. View